Abeona Therapeutics Inc.ABEO
Price (close)
$5.40
Market cap
$309.0M
P/E
—
Revenue (TTM)
$25.5M
Net income
-$62.9M
Dividend yield
—
1-year total return
0.7%
Net margin
-246.4%
Revenue growth
—
Debt / equity
0.12x
What Abeona Therapeutics Inc. does.
or the “Company”), is a commercial-stage biopharmaceutical company developing cell and gene therapies for life-threatening
therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (“RDEB”),
a serious and debilitating genetic skin disease. There is no cure for RDEB, and ZEVASKYN ® is the only FDA-approved product to treat RDEB wounds with
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $10.0M | $3.0M | $1.4M | $3.5M | — | $5.8M |
| Net income | -$84.2M | -$84.9M | -$39.7M | -$54.2M | -$63.7M | $71.2M |
| Free cash flow | -$36.4M | -$69.8M | -$43.6M | -$37.3M | -$58.5M | -$84.3M |
More on ABEO.
- Abeona Therapeutics Inc. summary
- Abeona Therapeutics Inc. financial statements
- Abeona Therapeutics Inc. key metrics
- Abeona Therapeutics Inc. health scores and style box
- Abeona Therapeutics Inc. earnings
- Abeona Therapeutics Inc. dividends
- Abeona Therapeutics Inc. valuation
- Abeona Therapeutics Inc. ownership and insiders
- Abeona Therapeutics Inc. peers
Figures from Abeona Therapeutics Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.